Company Metrics

• 0 P/E
• 18.72 P/S
• 7.96 P/B
• -0.21 EPS
• -450.17% Cash ROIC
• 4.26 Cash Ratio
• 0 / 0% Dividend
• 150,892.00 Avg. Vol.
• 24.76M Shares
• 78.6M Market Cap.

Company Description

Prana Biotechnology Limited engages in the research and development of therapeutic drugs for neurological diseases in Australia. The company primarily focuses on the Alzheimer's, Parkinson's, and Huntington's diseases, as well as various age-related degenerative disorders. Its development stage product line includes PBT2, a phase IIb clinical product intended for the Alzheimer's disease; and PBT2, a phase IIa clinical product for the Huntington's disease. The company's products under research comprise PBT434 for the Parkinson's disease, PBT519 for brain cancer, 4E10 for the Alzheimer's disease, and PB1568 for the Alzheimer's disease imaging. Prana Biotechnology Limited was founded in 1997 and is based in Parkville, Australia.
less

Prana Biotechnology Limited engages in the research and development of therapeutic drugs for neurological diseases in Australia. The company primarily focuses on the Alzheimer's, Parkinson's, and Huntington's diseases, as well as various age-related degenerative disorders. Its development stage product line includes PBT2, a phase IIb clinical product intended for the Alzheimer's disease; and PBT2,...
more

News